Stephanie Ritz, PhD
Medical Writer — Cost & Access Transparency
PhD scientist and independent medical writer. Stephanie writes for SunnyPharma across HIV, hepatitis C, weight management, and anticoagulant therapy — translating clinical evidence into plain-language cost and access guidance for patients who need it.
The Difference a Scientist’s Training Makes
Most medical content gets written backward. A writer reads the trial, summarizes the headline, and hands the patient a list of side effects. Stephanie writes the other way. She starts with the question a real patient is trying to answer — “is the generic the same drug?”, “will my insurance actually cover this?”, “what happens if I can’t afford a refill this month?” — and then walks back to the evidence that answers it. The PhD trains her to read primary studies without filtering them through the press release. The independent-writer model means no manufacturer sets her brief.
On a SunnyPharma page, that training shows up in the structure. Cost figures are dated and sourced. Access pathways name the program, the eligibility rule, and the application route. When the evidence does not yet say something — when the trial did not study a population, or when a comparison has never been run — she says so on the page, instead of papering the gap with hedging language. The goal is the same on every article: leave the patient with a decision they can actually make.
From the Lab to the Page
Stephanie earned her PhD in Cellular, Developmental, and Molecular Biology with an emphasis in Cancer Biology from the University of Alabama at Birmingham, and completed the Writing in the Sciences program through Stanford University School of Medicine. The PhD is the scientific foundation. The Stanford program is where she learned to write so a non-specialist reader could follow the reasoning, not just the conclusion.
Before launching her independent medical writing practice through Oncology Intellect LLC, Stephanie spent more than a decade inside the commercial pharmaceutical sector as a subject-matter expert for market research and health economics work spanning multiple therapeutic areas across the US, EU5, and Japan. That experience gave her a working knowledge of how clinical evidence becomes commercial messaging — what gets emphasized, what gets quietly dropped, and where the gaps between the trial and the talking point tend to sit.
For SunnyPharma, she applies the same scientific reading discipline to a different category of work: cost-burdened patients trying to navigate access to expensive medications across HIV, HCV, weight management, and anticoagulant therapy. The HEOR background does a specific job — every article is screened for whether the cost and access information is current, accurate, and useful at the level of an actual prescription decision. Numbers without context aren’t useful. Context without numbers isn’t actionable. The articles try to deliver both.
Her process inverts the usual order. Most medical writers start with the source material and then think about the reader. Stephanie starts with a specific patient question and works backward to the evidence that answers it. The market research years trained her to identify what patients actually ask, before what they tell a researcher they want to know.
What Stephanie Contributes to SunnyPharma
Selected Editorial Topics & Coverage Areas
Stephanie’s writing for SunnyPharma is organized around specific patient questions across four therapeutic areas — the topics where cost transparency and plain-language clinical context most affect whether a patient can stay on therapy.
HIV antiretroviral cost & access — Brand pricing, generic timelines, copay-card mechanics, and AIDS Drug Assistance Program (ADAP) navigation across major US states.
Hepatitis C direct-acting antivirals — Treatment-course pricing, Medicaid coverage variation, and the access landscape for cure-rate medications like Mavyret and Epclusa.
Weight management & GLP-1 therapies — Cash pricing, insurance and Medicare coverage limits, and the compounded-version regulatory landscape for Wegovy, Zepbound, and Mounjaro.
Anticoagulant cost & access — Eliquis and Xarelto pricing under the 2026 Medicare-negotiated prices, manufacturer patient assistance, and the April 2028 generic apixaban timeline.
Cross-border medication access — Sourced comparisons of US, Canadian, and Mexican brand and generic pricing, with the regulatory and clinical context patients need before considering cross-border options.
Medicare IRA explainers — Why negotiated prices and pharmacy-counter prices often don’t match, how Part D tier placement affects out-of-pocket cost, and what to do when the savings don’t show up on a refill.
Writing Standards & Editorial Transparency
Every article Stephanie writes for SunnyPharma follows the publication’s editorial standards: cost figures are cited and dated, clinical claims trace to peer-reviewed sources or FDA prescribing information, and uncertainty is named on the page rather than smoothed over. Articles are independently medically reviewed before publication and editorially verified by Medical Editor Prof. Dr. Jürgen K. Rockstroh, who reviews contributor credentials and disclosures across the SunnyPharma editorial team.
Editorial independence. SunnyPharma does not accept advertising and does not earn referral revenue from any manufacturer, pharmacy, or assistance program named in its articles. Stephanie is paid by SunnyPharma for her writing and holds no financial interest in any drug, manufacturer, or program covered in her articles. Any prior pharmaceutical-sector consulting work is disclosed in the credentials section below and does not bear on current SunnyPharma coverage.
Credentials & Background
PhD, Cellular, Developmental and Molecular Biology (Cancer Biology emphasis) — University of Alabama at Birmingham.
Writing in the Sciences — Stanford University School of Medicine (continuing professional education program).
Founder, Oncology Intellect LLC — Independent medical writing practice serving pharma, biotech, and healthcare clients across multiple therapeutic areas and global markets (US, EU5, Japan).
Health economics and outcomes research (HEOR) experience — Multi-year subject-matter expert role across market research and health economics projects spanning multiple therapeutic areas.
LinkedIn — linkedin.com/in/stephanie-ritz-phd
Areas of Expertise
Why Stephanie Writes for SunnyPharma
The patients SunnyPharma writes for are not making abstract drug-policy decisions. They are deciding whether to fill a prescription this month, whether to ration a refill, whether to ask a doctor about a switch they cannot afford to make wrong. Those decisions deserve information that is sourced, current, and honest about what the evidence does not say. Stephanie writes for SunnyPharma because that is the kind of medical content her training prepared her to produce — and because cost-burdened patients are exactly the audience for whom that work matters most.